Monrovia-based Xencor, which develops pharmaceuticals to fight cancer and autoimmune diseases, reported a net income for the first quarter ended March 31, 2022 of $23.6 million, or $.39 per share, compared to a net loss of $2.5 million, or $(.04) per share for the same period in 2021. https://tny.im/SKQSV
- Brad Haugaard
No comments:
Post a Comment